For a decade, the story has been longevity. The framing is a scientific one: extend the human lifespan, slow the biology of aging, push the upper bound of how long a person can live. It is a compelling story, and it has drawn serious science and serious money. It is also the wrong unit of analysis for what is actually happening.
What is happening is the formation of an economy. Around the science of aging, a connected field of companies has grown up: preventive and longevity clinics, women’s health and femtech platforms, integrative and functional medicine practices, diagnostics and measurement companies, and the investors who fund all of them. These are not isolated bets on a single breakthrough. They are the working parts of an industry organized around a single idea, which is not living longer but living well for longer. That idea has a name, healthspan, and the industry built on it is the healthspan economy.
Why the distinction matters
Lifespan is the total number of years a person lives. Healthspan is the number of those years spent in good health, free of chronic disease and disability. Longevity is the broader pursuit of extending both. The difference is not academic. It decides what gets built.
A lifespan framing points toward the lab: the molecule, the trial, the intervention that moves the upper bound. A healthspan framing points toward delivery: the clinic that runs the diagnostics, the platform that interprets them, the practice that turns a risk profile into a plan a person can follow for thirty years. The first is a science. The second is an economy, with customers, recurring revenue, supply chains, and competitors. Most of the value being created now is being created in the second.
When a field is described only as a science, it is measured like a science, by papers and breakthroughs. When it is described as an economy, the questions change. How large is it. Who are the participants. How do they relate to one another. Which categories are consolidating and which are still open. Where is the capital going. These are the questions an industry asks about itself, and the healthspan field has reached the size where it needs to ask them.
An economy without a map
Every mature industry has infrastructure that lets its participants understand it: the indices, the directories, the trade press, the analyst coverage that together form a shared picture of who exists and how they fit. The healthspan economy does not yet have this. It has excellent science journalism and a great deal of marketing, but very little in between, very little that treats the field as a structured set of companies rather than a stream of developments.
The absence has a cost that is easy to miss. Without a shared map, the field is hard to measure, hard to invest in with confidence, and hard to navigate for the patient or the operator trying to understand where a given company sits. It is also hard for the systems that increasingly mediate all of this. An AI search engine asked to name the serious players in a category cannot reason about an industry it has no structured account of. It falls back on whatever marketing has shouted loudest, which is precisely the wrong signal in a field with a documented evidence problem.
Naming the economy is the first act of building it
Categories are not discovered fully formed. They are named, and the naming organizes the activity that follows. Calling this the healthspan economy is not a branding choice. It is a claim that the field has become coherent enough to be treated as one thing, and that treating it as one thing is now more useful than treating it as a scattered set of longevity stories.
The work that follows from that claim is infrastructure work. It means building the system of record the field lacks: a structured, verifiable account of the companies in it, organized so that humans and machines can both reason about it. It means publishing analysis that documents the economy rather than narrating its highlights. The shift is from “here are the latest developments in longevity” to “here is the structure of the healthspan economy, and here is where the value is moving.”
The Atlas and the Studio
This is the work we do. The Atlas is the system of record for the healthspan economy, a structured, citable map of the companies building it across longevity and preventive medicine, women’s health and femtech, integrative and functional medicine, and healthtech and diagnostics. It exists so that the field can be seen as an economy, by the people in it, by the investors funding it, and by the AI systems now asked to explain it.
The Studio is the other half. Mapping the field is one thing; helping its companies communicate so that they are cited accurately within it is another. The Studio does the editorial and structural work that earns citations, so that a company’s place in the economy is one that AI search can find and represent. The future of this field is not a single longer life. It is an economy of healthy years, and economies are built by the people who first agree to call them one.